Roles of nitric oxide in tumor growth.

Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42

Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest (1997) 4.92

Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest (1997) 3.39

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13

Inducible nitric oxide synthase in human diseases. Clin Exp Immunol (1998) 2.21

Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87

Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol (1997) 1.79

Retracted Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. J Biol Chem (2009) 1.56

Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A (2005) 1.55

Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest (2010) 1.52

Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol (1997) 1.31

The multiplex function of nitric oxide in (auto)immunity. J Exp Med (1998) 1.29

Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer (1999) 1.29

Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br J Cancer (2003) 1.26

Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol (1999) 1.22

Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer (1998) 1.20

Inorganic/Organic Hybrid Silica Nanoparticles as a Nitric Oxide Delivery Scaffold. Chem Mater (2008) 1.15

Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro. Am J Pathol (1997) 1.13

Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci U S A (1998) 1.12

Translational research involving oxidative stress and diseases of aging. Free Radic Biol Med (2011) 1.10

Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer (1998) 1.10

Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc Natl Acad Sci U S A (2000) 1.10

The reemergence of nitric oxide and cancer. Nitric Oxide (2008) 1.09

Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer (2007) 1.09

Nitric oxide regulates lung carcinoma cell anoikis through inhibition of ubiquitin-proteasomal degradation of caveolin-1. J Biol Chem (2009) 1.08

Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med (2005) 1.07

Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide. Biochemistry (2009) 1.07

Inducible heat shock protein 70 prevents multifocal flat dysplastic lesions and invasive tumors in an inflammatory model of colon cancer. Carcinogenesis (2008) 1.07

Nitric oxide and cancer therapy: the emperor has NO clothes. Curr Pharm Des (2010) 1.05

Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol (2003) 1.04

Inhibition of protein synthesis by nitric oxide correlates with cytostatic activity: nitric oxide induces phosphorylation of initiation factor eIF-2 alpha. Mol Med (1998) 1.03

Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice. EMBO J (2001) 1.02

Adenocarcinoma within a diverticulum: a common tumor arising in an uncommon location. Dig Dis Sci (2002) 1.02

Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res (2009) 1.01

Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. Am J Pathol (2003) 1.01

Nitric oxide and cancer. World J Hepatol (2010) 1.01

Vascular permeability and drug delivery in cancers. Front Oncol (2013) 0.99

EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase. Biochem Biophys Res Commun (2008) 0.99

Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. Cell Cycle (2011) 0.99

The role of microenvironment in tumor angiogenesis. Genes Nutr (2008) 0.98

In vivo footprinting of the mouse inducible nitric oxide synthase gene: inducible protein occupation of numerous sites including Oct and NF-IL6. Nucleic Acids Res (1996) 0.98

The role of tumour-derived iNOS in tumour progression and angiogenesis. Br J Cancer (2010) 0.97

miRNA-939 regulates human inducible nitric oxide synthase posttranscriptional gene expression in human hepatocytes. Proc Natl Acad Sci U S A (2012) 0.97

iNOS-selective inhibitors for cancer prevention: promise and progress. Future Med Chem (2012) 0.96

Gasotransmitters in cancer: from pathophysiology to experimental therapy. Nat Rev Drug Discov (2015) 0.96

Expression of inducible nitric oxide synthase and its involvement in pulmonary granulomatous inflammation in rats. Am J Pathol (1996) 0.96

Nitric oxide reversibly inhibits the epidermal growth factor receptor tyrosine kinase. Biochem J (1997) 0.96

Decreased Helicobacter pylori associated gastric carcinogenesis in mice lacking inducible nitric oxide synthase. Gut (2004) 0.96

Immune cells and angiogenesis. J Cell Mol Med (2009) 0.96

Expression of inducible nitric oxide synthase in human gastric cancer. World J Gastroenterol (1999) 0.95

Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br J Cancer (2000) 0.95

Immunological mechanism of the low-dose radiation-induced suppression of cancer metastases in a mouse model. Dose Response (2009) 0.94

Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer (2002) 0.93

The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer. Br J Cancer (1998) 0.92

Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med (2008) 0.92

An intratracheal instillation bioassay system for detection of lung toxicity due to fine particles in f344 rats. J Toxicol Pathol (2009) 0.91

Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis. Br J Cancer (2005) 0.90

Cancer cell metabolism and the modulating effects of nitric oxide. Free Radic Biol Med (2014) 0.90

Role of nitric oxide and its metabolites as potential markers in lung cancer. Ann Thorac Med (2010) 0.90

Iron: an emerging factor in colorectal carcinogenesis. World J Gastroenterol (2010) 0.90

iNOS: a potential therapeutic target for malignant glioma. Curr Mol Med (2013) 0.89

Multiple myeloma macrophages: pivotal players in the tumor microenvironment. J Oncol (2013) 0.89

Nitric oxide synthase is expressed in human macrophages during foreign body inflammation. Am J Pathol (1997) 0.89

Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc Natl Acad Sci U S A (2005) 0.89

Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer. World J Gastroenterol (2005) 0.89

Expression of NOS and HIF-1alpha in human colorectal carcinoma and implication in tumor angiogenesis. World J Gastroenterol (2006) 0.87

Synthesis and biological evaluation of nitric oxide-releasing derivatives of oleanolic acid as inhibitors of HepG2 cell apoptosis. Bioorg Med Chem Lett (2007) 0.87

rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. J Transl Med (2003) 0.87

Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res (2011) 0.87

Regulation of apoptosis-related genes by nitric oxide in cancer. Nitric Oxide (2008) 0.87

Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J Gastroenterol (2005) 0.87

Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs (2002) 0.86

Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges. Mediators Inflamm (2012) 0.86

Nitric oxide synthase expression in human bladder cancer and its relation to angiogenesis. Urol Res (2003) 0.86

Effect of low doses of low-let radiation on the innate anti-tumor reactions in radioresistant and radiosensitive mice. Dose Response (2012) 0.85

Role of nitric oxide in pancreatic tumour growth: in vivo and in vitro studies. Br J Cancer (1998) 0.84

Inflammation-related gene variants as risk factors for pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2011) 0.84

Increasing the endogenous NO level causes catalase inactivation and reactivation of intercellular apoptosis signaling specifically in tumor cells. Redox Biol (2015) 0.84

Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. J Clin Pathol (2005) 0.84

Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer. Br J Cancer (1999) 0.84

Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci (2010) 0.84

Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1998) 0.84

Pro-survival and pro-growth effects of stress-induced nitric oxide in a prostate cancer photodynamic therapy model. Cancer Lett (2013) 0.84

Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia. Br J Cancer (1996) 0.83

Differential uptake of chemically modified cowpea mosaic virus nanoparticles in macrophage subpopulations present in inflammatory and tumor microenvironments. Biomacromolecules (2012) 0.83

Regulation of induction of nitric oxide synthase and the inhibitory actions of dexamethasone in the human intestinal epithelial cell line, Caco-2: influence of cell differentiation. Br J Pharmacol (1999) 0.83

TAp73 induction by nitric oxide: regulation by checkpoint kinase 1 (CHK1) and protection against apoptosis. J Biol Chem (2011) 0.83

Nitric oxide production upregulates Wnt/β-catenin signaling by inhibiting Dickkopf-1. Cancer Res (2013) 0.83

Rapid upregulation of cytoprotective nitric oxide in breast tumor cells subjected to a photodynamic therapy-like oxidative challenge. Photochem Photobiol (2011) 0.83

Characterization of C-alkyl amidines as bioavailable covalent reversible inhibitors of human DDAH-1. ChemMedChem (2011) 0.83

Molecular mechanisms of cholangiocarcinoma. World J Gastrointest Pathophysiol (2010) 0.82

Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol (2005) 0.82

Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells. J Pharmacol Exp Ther (2013) 0.82

Heme oxygenase-1 accelerates protumoral effects of nitric oxide in cancer cells. Virchows Arch (2005) 0.81

Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213). Chem Res Toxicol (2013) 0.80

Accelerated migration and invasion of prostate cancer cells after a photodynamic therapy-like challenge: Role of nitric oxide. Nitric Oxide (2015) 0.80

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer (2000) 0.80

Differential activity of NO synthase inhibitors as chemopreventive agents in a primary rat tracheal epithelial cell transformation system. Neoplasia (2002) 0.79

Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density. World J Gastroenterol (2004) 0.79

Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44

An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide. Nucleic Acids Res (1989) 10.50

Nitric oxide synthases in mammals. Biochem J (1994) 6.50

Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J Biol Chem (1992) 4.88

Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci U S A (1992) 4.32

Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet (1992) 3.77

Synthesis of nitrite and nitrate in murine macrophage cell lines. Cancer Res (1987) 2.69

Nitric oxide synthase activity in human gynecological cancer. Cancer Res (1994) 2.27

Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem Biophys Res Commun (1991) 2.26

Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc Natl Acad Sci U S A (1993) 2.10

Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer (1994) 1.65

Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci U S A (1994) 1.65

Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res (1991) 1.64

Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer (1994) 1.39

Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res (1993) 1.35

Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res (1991) 1.30

Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers. Eur J Pharmacol (1993) 1.25

Tumor biology. Am J Clin Oncol (1988) 1.04

Localization of nitric oxide synthase in the mouse olfactory and vomeronasal system: a histochemical, immunological and in situ hybridization study. Eur J Neurosci (1993) 0.94

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44

Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19

Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93

Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85

Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34

Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79

L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77

Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69

Nitric oxide synthases in mammals. Biochem J (1994) 6.50

A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30

Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20

Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87

Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36

Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23

A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14

The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88

Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66

Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55

Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54

Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49

Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44

Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23

Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19

Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11

An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98

Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74

Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74

Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70

Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci (1995) 3.65

The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63

Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med (1991) 3.50

Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett (1991) 3.43

Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29

Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28

The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25

Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20

Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15

Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14

Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10

An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07

Structure of Bordetella pertussis virulence factor P.69 pertactin. Nature (1996) 3.02

Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93

Association of alkaline phosphatase with an autoantigen recognised by circulating anti-neutrophil antibodies in systemic vasculitis. Lancet (1987) 2.85

Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83

Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun (1991) 2.79

Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. Biochem J (1967) 2.78

Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun (1989) 2.73

Nitric oxide synthase activities in human myocardium. Lancet (1993) 2.72

Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70

Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68

Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67

Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63

Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis (1989) 2.58

NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol (1989) 2.53

Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet (1994) 2.53

Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51

Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. Biochem J (1992) 2.51

Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc Natl Acad Sci U S A (1991) 2.49

Standardization of clinical enzyme assays. J Clin Pathol (1971) 2.49

Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48

Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet (1992) 2.44

S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol (1992) 2.39

The role of TH1 and TH2 cells in a rodent malaria infection. Science (1993) 2.38

Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Biotechnology (N Y) (1992) 2.38

Multiple opiate receptor sites on primary afferent fibres. Nature (1980) 2.34

General-practitioner obstetric beds in a consultant unit. Br Med J (1968) 2.34

Computer service for obstetric records. Br Med J (1971) 2.32

Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol (1992) 2.32

Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br J Pharmacol (1988) 2.32

Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun (1990) 2.31

Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun (1990) 2.31

A lethal role for lipid A in Salmonella infections. Mol Microbiol (1998) 2.30

A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28

Nitric oxide synthase activity in human gynecological cancer. Cancer Res (1994) 2.27

Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol (1999) 2.26

Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (1980) 2.24

Nitric oxide synthase activity in human breast cancer. Br J Cancer (1995) 2.22

Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet (1993) 2.20

cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A (1996) 2.17

A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. Eur J Immunol (1991) 2.15

Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther (1984) 2.12

Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc Natl Acad Sci U S A (1993) 2.10

Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol (1992) 2.09

Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. Biochem Biophys Res Commun (1992) 2.08

Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol (1973) 2.07

The effects of prostagladin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations [proceedings]. Br J Pharmacol (1976) 2.06

Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microb Pathog (1992) 2.04

Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet (1990) 2.04

Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci U S A (2001) 2.03

Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sang (2012) 2.03

Mechanism of action of some inhibitors of endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1986) 2.03

Quality control in routine clinical chemistry. Adv Clin Chem (1967) 2.02

Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol (1982) 2.01

The effects of BW755C and other anti-inflammatory drugs on eicosanoid concentrations and leukocyte accumulation in experimentally-induced acute inflammation. J Pharm Pharmacol (1983) 2.00